| Literature DB >> 31901898 |
Xiaoxuan Ling1,2, Yinyan Li1, Fuman Qiu1, Xiaoxiao Lu3, Lei Yang1,4, Jinbin Chen1,4, Tiegang Li1,5, Di Wu1,5, Huali Xiong1, Wenpeng Su1, Dongsheng Huang6, Jiansong Chen1, Binyao Yang1, Hongjun Zhao1, Chenli Xie7, Yifeng Zhou8, Jiachun Lu1,4.
Abstract
Lnc-BMP1-1 is a lncRNA transcribed from SFTPC (surfactant associated protein C), a lung tissue specific gene encoding pulmonary-associated surfactant protein C (SPC) that is solely secreted by alveolar typeⅡ epithelial cells, among which the ones with SFTPC+ might be transformed into lung adenocarcinoma cells. Caveolin-1 (Cav-1) is a candidate tumor suppressor gene and is vital for coping with oxidative stress induced by cigarette smoke. When comparing lung cancer tissues with their adjacent normal tissues, the expression of lnc-BMP1-1 were decreased, especially in patients with cigarette smoking history (P=0.027), and positively associated with the expression of Cav-1 (P<0.001). When comparing to A549 cells transfected with empty vector (A549-NC cells), the expression level of Cav-1 in A549 cells with over-expressed lnc-BMP1-1 (A549-BMP cells) was increased along with the decreased level of HDAC2 protein. The drug sensitivity of A549-BMP cells to Doxorubicin hydrochloride (DOX) was increased; the growth and migration capability of A549-BMP cells were inhibited along with the decreased protein level of Bcl-2 and DNMT3a; the growth of tumor in nude mice injected with A549-BMP cells were inhibited, too. Furthermore, the lnc-BMP1-1 and Cav-1 expression was also down-regulated in the human bronchial epithelial (16HBE) cells treated with cigarette smoke extract (CSE).Entities:
Keywords: Cav-1; cigarette smoke; epigenetic modification; lnc-BMP1-1; lung cancer
Year: 2020 PMID: 31901898 PMCID: PMC6977698 DOI: 10.18632/aging.102633
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1The decrease of (A) The expression of lnc-BMP1-1 was decreased in lung cancer patients; (B) The expression of Cav-1 was decreased in lung cancer patients; (C) The relationship between lnc-BMP1-11 and Cav-1 expression; (D) The expression of lnc-BMP1-1 in types of lung cancer cells. RNA expression was analyzed using RT-PCR, the RNA levels were normalized against β-actin mRNA. Each bar represents the means ± SD of three independent experiments.
The expression of lnc-BMP1-1 and clinical characteristics of lung cancer patients.
| Age | ||||
| <60 | 139 (84.2) | 26 (15.8) | 165 (56.3) | 0.499 |
| ≥60 | 104 (81.2) | 24 (18.8) | 128 (43.7) | |
| Gender | ||||
| Male | 177 (85.5) | 30 (14.5) | 207 (70.6) | 0.069 |
| Female | 66 (76.7) | 20 (23.3) | 86 (29.4) | |
| Smoking | ||||
| No | 77 (76.2) | 24 (23.8) | 101 (34.5) | 0.027 |
| Yes | 166 (86.5) | 26 (13.5) | 192 (65.5) | |
| Drinking | ||||
| No | 185 (83.3) | 37 (16.7) | 222 (75.8) | 0.749 |
| Yes | 58 (81.7) | 13 (18.3) | 71 (24.2) | |
| tumor history | ||||
| No | 213 (83.5) | 42 (16.5) | 255 (87.0) | 0.484 |
| Yes | 30 (78.9) | 8 (21.1) | 38 (13.0) | |
| Lc history | ||||
| No | 228 (83.5) | 45 (16.5) | 273 (93.2) | 0.354 |
| Yes | 15 (75.0) | 5 (25.0) | 20 (6.8) | |
| Clinical Stage | ||||
| Ⅰ+Ⅱ | 93 (86.9) | 14 (13.1) | 107 (36.5) | 0.170 |
| Ⅲ+Ⅳ | 150 (80.6) | 36 (19.4) | 186 (63.5) | |
| Histological subtype | ||||
| Adenocarcinoma | 112 (82.4) | 24 (17.6) | 136 (46.4) | 0.189 |
| Squamous carcinoma | 70 (79.5) | 18 (20.5) | 88 (30.0) | |
| Large cell carcinoma | 8 (72.7) | 3 (27.3) | 11 (3.8) | |
| Small cell carcinoma | 27 (96.4) | 1 (3.6) | 28 (9.6) | |
| Others | 26 (86.7) | 4 (13.3) | 30 (10.2) | |
| T status | ||||
| 1+2 | 126 (80.3) | 31 (19.7) | 157 (53.6) | 0.190 |
| 3+4 | 117(86.0) | 19 (14.0) | 136 (46.4) | |
| N status | ||||
| 0 | 91 (79.1) | 24 (20.9) | 115 (39.2) | 0.164 |
| 1+2+3 | 152 (85.4) | 26 (14.6) | 178 (60.8) | |
| M status | ||||
| 0 | 161 (78.5) | 44 (21.5) | 205 (70.0) | 0.002 |
| 1 | 82 (93.2) | 6 (6.8) | 88 (30.0) | |
NOTE: Comparisons between groups were analyzed as described in the Methods. Groups: High=patients with higher expression of lnc-BMP1-1 in lung cancer tissues compared with their adjacent normal lung tissues; Low = patients with lower expression of lnc-BMP1-1 in lung cancer tissues compared with their adjacent normal lung tissues. a, Pearson χ2 test for high vs. low gene (lnc-BMP1-1 or Cav-I) expression groups combining clinical characteristics. Significance (bold values), p<0.05.
Abbreviations: N, number of subjects in each group; Lc history, lung cancer history.
Figure 2The cell growth or migration of lung cancer cells with lnc-BMP1-1 over-expression vs. NC cells. (A) The cell proliferation of A549-BMP vs. A549-NC, (B) PC9-BMP vs. PC9-NC, (C) GLC82-BMP vs. GLC82-NC, respectively; (D) Comparison of the wound widths (40x) of lung cancer cells with Inc-BMP1-1 over-expression vs. NC cells after 72 hrs, the relative bar graph are A549-BMP vs. A549-NC(E), PC9-BMP vs. PC9-NC(F), GLC82-BMP vs. GLC82-NC(G); the migration capacity of both A549-BMP and GLC82BMP cells were reduced; however, there's no significant difference of PC9-BMP vs. PC9-NC cells; with transwell migration experiments (40 x), the cell migration capacity of A549-BMP vs. A549-NC was proved to be decreased again (H), the relative bar graph was A549-BMP vs. A549-NC(I), PC9-BMP vs. PC9-NC(J), GLC82-BMP vs. GLC82NC (K), respectively. Data are represented as means ± SD. *P < 0.05, ns P> 0.05
Figure 3The RNA or protein expression changes of lung cancer cells with (A) The protein expression of Bcl-2, Cav-1 and DNMT3a in different lung cancer cell lines with lnc-BMP1-1 over-expression vs. NC cells; the protein expression were detected using western blotting analyses, protein expression was normalized against GAPDH or α-tubulin protein; the value above each band indicates the fold change of protein expression relative to their control; (B) The cell viability of CSE (vs. DMSO) treated 16HBE cells at 5th passage; (C) The cell viability of CSE (vs. DMSO) treated 16HBE cells at 10th passage; (D) The expression of lnc-BMP1-1, Cav-1 were reduced in CSE treated 16HBE cells both in 5th and 10th passage, and made greater decline in 10th than in 5th passage (the same gene was compared in 5th and 10th generation of CSE treated 16HBE cells, #P<0.05, ##P<0.01). The mRNA expression of Cav-1 in A549-BMP vs. A549-NC (E), GLC82-BMP vs. GLC82-NC(F), respectively; In A549 cells treated with TSA, the expression of lnc-BMP1-1 (G) and Cav-7 (H) were increased, while DNMT3a (I) was decreased; The protein expression of HDAC2 (J) was decreased in A549-BMP cells. Data are represented as means ± SD. *P< 0.05, **P<0.01.
The expression of Cav-1 and clinical characteristics of lung cancer patients.
| Age | ||||
| <60 | 133(80.6) | 32(19.4) | 165(56.3) | 0.757 |
| ≥60 | 105(82.0) | 23(18.0) | 128(43.7) | |
| Gender | ||||
| Male | 171(82.6) | 36(17.4) | 207(70.6) | 0.348 |
| Female | 67(77.9) | 19(22.1) | 86(29.4) | |
| Smoking | ||||
| No | 74(73.3) | 27(26.7) | 101(34.5) | 0.011 |
| Yes | 164(85.4) | 28(14.6) | 192(65.5) | |
| Drinking | ||||
| No | 180(81.1) | 42(18.9) | 222(75.8) | 0.909 |
| Yes | 58(81.7) | 13(18.3) | 71(24.2) | |
| tumor history | ||||
| No | 207(81.1) | 48(18.9) | 255(87.0) | 0.953 |
| Yes | 31(81.6) | 7 (18.4) | 38(13.0) | |
| Lc history | ||||
| No | 222(81.3) | 51(18.7) | 273(93.2) | 0.775 |
| Yes | 16(80.0) | 4(20.0) | 20 (6.8) | |
| Clinical Stage | ||||
| Ⅰ+Ⅱ | 87(81.3) | 20(18.7) | 107(36.5) | 0.979 |
| Ⅲ+Ⅳ | 151(81.2) | 35(18.8) | 186(63.5) | |
| Histological subtype | ||||
| Adenocarcinoma | 113(83.1) | 23(16.9) | 136(46.4) | 0.149 |
| Squamous carcinoma | 72(81.8) | 16(18.2) | 88(30.0) | |
| Large cell carcinoma | 6(54.5) | 5(45.5) | 11(3.8) | |
| Small cell carcinoma | 21(75.0) | 7(25.0) | 28(9.6) | |
| Others | 26(86.7) | 4(13.3) | 30(10.2) | |
| T status | ||||
| 1+2 | 128(81.5) | 29(18.5) | 157(53.6) | 0.887 |
| 3+4 | 110(80.9) | 26(19.1) | 136(46.4) | |
| N status | ||||
| 0 | 93(80.9) | 22(19.1) | 115(39.2) | 0.899 |
| 1+2+3 | 145(81.5) | 33(18.5) | 178(60.8) | |
| M status | ||||
| 0 | 171(83.4) | 34(16.6) | 205(70.0) | 0.144 |
| 1 | 67(76.1) | 21(23.9) | 88(30.0) | |
NOTE: Comparisons between groups were analyzed as described in the Methods. Groups: High=patients with higher expression of Cav-1 in lung cancer tissues compared with their adjacent normal lung tissues; Low = patients with lower expression of Cav-1 in lung cancer tissues compared with their adjacent normal lung tissues. a, Pearson χ2 test. Significance (bold values), p<0.05.
Abbreviations: N, number of subjects in each group; Lc history, lung cancer history.
Figure 4The tumor growth in nude mice and the results of anti-cancer drug trial in A549-BMP vs. A549-NC cells. (A) Tumor of A549-BMP vs A549-NC cells; (B) Tumor volume and tumor weight; (C) The HE staining of nude mice tumor tissues; (D) The drug sensitivity to doxorubicin hydrochloride was enhanced in A549-BMP vs A549-NC cells. Data are represented as means ± SD. *P< 0.05, **P<0.01.